These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 26831665)

  • 1. DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC).
    Evelönn EA; Degerman S; Köhn L; Landfors M; Ljungberg B; Roos G
    Tumour Biol; 2016 Aug; 37(8):10219-28. PubMed ID: 26831665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma.
    Evelönn EA; Landfors M; Haider Z; Köhn L; Ljungberg B; Roos G; Degerman S
    BMC Cancer; 2019 Jan; 19(1):65. PubMed ID: 30642274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
    Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
    Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma.
    Eggers H; Steffens S; Grosshennig A; Becker JU; Hennenlotter J; Stenzl A; Merseburger AS; Kuczyk MA; Serth J
    Int J Oncol; 2012 May; 40(5):1650-8. PubMed ID: 22327210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.
    Lin YL; Gui SL; Guo H; Ma JG; Li WP
    Med Sci Monit; 2015 Sep; 21():2870-6. PubMed ID: 26404644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.
    Mendoza-Pérez J; Gu J; Herrera LA; Tannir NM; Zhang S; Matin S; Karam JA; Wood CG; Wu X
    Cancer; 2017 Sep; 123(18):3617-3627. PubMed ID: 28543182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Four-Gene Promoter Methylation Marker Panel Consisting of
    van Vlodrop IJH; Joosten SC; De Meyer T; Smits KM; Van Neste L; Melotte V; Baldewijns MMLL; Schouten LJ; van den Brandt PA; Jeschke J; Yi JM; Schuebel KE; Ahuja N; Herman JG; Aarts MJ; Bosman FT; Van Criekinge W; van Engeland M
    Clin Cancer Res; 2017 Apr; 23(8):2006-2018. PubMed ID: 27756787
    [No Abstract]   [Full Text] [Related]  

  • 8. Methylation Signature for Prediction of Progression Free Survival in Surgically Treated Clear Cell Renal Cell Carcinoma.
    Kang HW; Park H; Seo SP; Byun YJ; Piao XM; Kim SM; Kim WT; Yun SJ; Jang W; Shon HS; Ryu KH; Lee SC; Kim WJ; Kim YJ
    J Korean Med Sci; 2019 May; 34(19):e144. PubMed ID: 31099194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation of CRB3 is a prognostic biomarker in clear cell renal cell carcinoma.
    Li P; Liu J; Li J; Liu P
    Mol Biol Rep; 2019 Aug; 46(4):4377-4383. PubMed ID: 31147860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma.
    Fritz HKM; Lindgren D; Ljungberg B; Axelson H; Dahlbäck B
    Eur J Cancer; 2014 Jul; 50(10):1758-1765. PubMed ID: 24793999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.
    Nofech-Mozes R; Khella HW; Scorilas A; Youssef L; Krylov SN; Lianidou E; Sidiropoulos KG; Gabril M; Evans A; Yousef GM
    Cancer Med; 2016 Apr; 5(4):656-64. PubMed ID: 26860079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Expression of Stearoyl-CoA Desaturase 1 Predicts Poor Prognosis in Patients with Clear-Cell Renal Cell Carcinoma.
    Wang J; Xu Y; Zhu L; Zou Y; Kong W; Dong B; Huang J; Chen Y; Xue W; Huang Y; Zhang J
    PLoS One; 2016; 11(11):e0166231. PubMed ID: 27861513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent epigenetic suppression of tumor suppressor gene glutathione peroxidase 3 by promoter hypermethylation and its clinical implication in clear cell renal cell carcinoma.
    Liu Q; Jin J; Ying J; Sun M; Cui Y; Zhang L; Xu B; Fan Y; Zhang Q
    Int J Mol Sci; 2015 May; 16(5):10636-49. PubMed ID: 25970749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression.
    Peters I; Eggers H; Atschekzei F; Hennenlotter J; Waalkes S; Tränkenschuh W; Grosshennig A; Merseburger AS; Stenzl A; Kuczyk MA; Serth J
    BJU Int; 2012 Jul; 110(2 Pt 2):E144-52. PubMed ID: 22289415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic clustering of clear cell renal cell carcinoma based on array-comparative genomic hybridization: its association with DNA methylation alteration and patient outcome.
    Arai E; Ushijima S; Tsuda H; Fujimoto H; Hosoda F; Shibata T; Kondo T; Imoto I; Inazawa J; Hirohashi S; Kanai Y
    Clin Cancer Res; 2008 Sep; 14(17):5531-9. PubMed ID: 18765545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased expression of RASSF1A tumor suppressor gene is associated with worse prognosis in clear cell renal cell carcinoma.
    Klacz J; Wierzbicki PM; Wronska A; Rybarczyk A; Stanislawowski M; Slebioda T; Olejniczak A; Matuszewski M; Kmiec Z
    Int J Oncol; 2016 Jan; 48(1):55-66. PubMed ID: 26648328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERBB2 is a potential diagnostic and prognostic biomarker in renal clear cell carcinoma.
    Gao WN; Chen LG; Bao LR; He N; Hu TL; Lai C; Xu RF; Wang XF; Wang JY; Zhao JR; Meng Y
    Sci Rep; 2024 Oct; 14(1):22775. PubMed ID: 39353993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PAI-1 expression and its regulation by promoter 4G/5G polymorphism in clear cell renal cell carcinoma.
    Choi JW; Lee JH; Park HS; Kim YS
    J Clin Pathol; 2011 Oct; 64(10):893-7. PubMed ID: 21725041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma.
    Wei JH; Haddad A; Wu KJ; Zhao HW; Kapur P; Zhang ZL; Zhao LY; Chen ZH; Zhou YY; Zhou JC; Wang B; Yu YH; Cai MY; Xie D; Liao B; Li CX; Li PX; Wang ZR; Zhou FJ; Shi L; Liu QZ; Gao ZL; He DL; Chen W; Hsieh JT; Li QZ; Margulis V; Luo JH
    Nat Commun; 2015 Oct; 6():8699. PubMed ID: 26515236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of TMEFF2 methylation on the tumor stage and survival outcome of clear cell renal cell carcinoma.
    Chen E; Zheng F; Yuan X; Ye Y; Li X; Dai Y; Chen L
    Cancer Biomark; 2017; 19(2):207-212. PubMed ID: 28128743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.